Literature DB >> 25205037

Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.

Ross Carruthers1, Shafiq U Ahmed2, Karen Strathdee3, Natividad Gomez-Roman4, Evelyn Amoah-Buahin5, Colin Watts6, Anthony J Chalmers7.   

Abstract

Resistance to radiotherapy in glioblastoma (GBM) is an important clinical problem and several authors have attributed this to a subpopulation of GBM cancer stem cells (CSCs) which may be responsible for tumour recurrence following treatment. It is hypothesised that GBM CSCs exhibit upregulated DNA damage responses and are resistant to radiation but the current literature is conflicting. We investigated radioresistance of primary GBM cells grown in stem cell conditions (CSC) compared to paired differentiated tumour cell populations and explored the radiosensitising effects of the ATM inhibitor KU-55933. We report that GBM CSCs are radioresistant compared to paired differentiated tumour cells as measured by clonogenic assay. GBM CSC's display upregulated phosphorylated DNA damage response proteins and enhanced activation of the G2/M checkpoint following irradiation and repair DNA double strand breaks (DSBs) more efficiently than their differentiated tumour cell counterparts following radiation. Inhibition of ATM kinase by KU-55933 produced potent radiosensitisation of GBM CSCs (sensitiser enhancement ratios 2.6-3.5) and effectively abrogated the enhanced DSB repair proficiency observed in GBM CSCs at 24 h post irradiation. G2/M checkpoint activation was reduced but not abolished by KU-55933 in GBM CSCs. ATM kinase inhibition overcomes radioresistance of GBM CSCs and, in combination with conventional therapy, has potential to improve outcomes for patients with GBM.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATM; Cancer stem cells; DNA damage response; Glioblastoma; Radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 25205037      PMCID: PMC5528679          DOI: 10.1016/j.molonc.2014.08.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  44 in total

1.  Terminally differentiated astrocytes lack DNA damage response signaling and are radioresistant but retain DNA repair proficiency.

Authors:  L Schneider; M Fumagalli; F d'Adda di Fagagna
Journal:  Cell Death Differ       Date:  2011-10-07       Impact factor: 15.828

2.  Comparative analysis of DNA repair in stem and nonstem glioma cell cultures.

Authors:  Monica Ropolo; Antonio Daga; Fabrizio Griffero; Mara Foresta; Gianluigi Casartelli; Annalisa Zunino; Alessandro Poggi; Enrico Cappelli; Gianluigi Zona; Renato Spaziante; Giorgio Corte; Guido Frosina
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  Ataxia telangiectasia mutated deficiency affects astrocyte growth but not radiosensitivity.

Authors:  E C Gosink; M J Chong; P J McKinnon
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.

Authors:  Laura Biddlestone-Thorpe; Muhammad Sajjad; Elizabeth Rosenberg; Jason M Beckta; Nicholas C K Valerie; Mary Tokarz; Bret R Adams; Alison F Wagner; Ashraf Khalil; Donna Gilfor; Sarah E Golding; Sumitra Deb; David G Temesi; Alan Lau; Mark J O'Connor; Kevin S Choe; Luis F Parada; Sang Kyun Lim; Nitai D Mukhopadhyay; Kristoffer Valerie
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

6.  Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein.

Authors:  Alessandro Raso; Donatella Vecchio; Enrico Cappelli; Monica Ropolo; Alessandro Poggi; Paolo Nozza; Roberto Biassoni; Samantha Mascelli; Valeria Capra; Fotios Kalfas; Paolo Severi; Guido Frosina
Journal:  Brain Pathol       Date:  2012-02-21       Impact factor: 6.508

7.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.

Authors:  Myung Jin Son; Kevin Woolard; Do-Hyun Nam; Jeongwu Lee; Howard A Fine
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

8.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

10.  Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics.

Authors:  Mariella Mannino; Natividad Gomez-Roman; Helfrid Hochegger; Anthony J Chalmers
Journal:  Stem Cell Res       Date:  2014-05-11       Impact factor: 2.020

View more
  51 in total

1.  BECN1 promotes radiation-induced G2/M arrest through regulation CDK1 activity: a potential role for autophagy in G2/M checkpoint.

Authors:  Ruixue Huang; Shanshan Gao; Yanqin Han; Huacheng Ning; Yao Zhou; Hua Guan; Xiaodan Liu; Shuang Yan; Ping-Kun Zhou
Journal:  Cell Death Discov       Date:  2020-08-05

2.  Radiosensitization of cancer stem cells in glioblastoma by the simultaneous inhibition of parallel DNA damage response pathways.

Authors:  Yasunori Fukumoto
Journal:  Ann Transl Med       Date:  2017-05

3.  A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR.

Authors:  Siyuan Tang; Zhentian Li; Lifang Yang; Liangfang Shen; Ya Wang
Journal:  Int J Radiat Biol       Date:  2020-01-08       Impact factor: 2.694

Review 4.  GBM radiosensitizers: dead in the water…or just the beginning?

Authors:  Ranjit S Bindra; Anthony J Chalmers; Sydney Evans; Mark Dewhirst
Journal:  J Neurooncol       Date:  2017-07-31       Impact factor: 4.130

5.  Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins.

Authors:  Vashendriya V V Hira; Jill R Wormer; Hala Kakar; Barbara Breznik; Britt van der Swaan; Renske Hulsbos; Wikky Tigchelaar; Zbynek Tonar; Mohammed Khurshed; Remco J Molenaar; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2018-01-03       Impact factor: 2.479

6.  Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1.

Authors:  Wen Song; Cuiping Guo; Jianxiong Chen; Shiyu Duan; Yukun Hu; Ying Zou; Honggang Chi; Jian Geng; Jun Zhou
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-20

7.  When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers.

Authors:  Nuala McCabe; Steven M Walker; Richard D Kennedy
Journal:  Mol Cell Oncol       Date:  2015-06-10

8.  Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells.

Authors:  Ross D Carruthers; Shafiq U Ahmed; Shaliny Ramachandran; Karen Strathdee; Kathreena M Kurian; Ann Hedley; Natividad Gomez-Roman; Gabriela Kalna; Mathew Neilson; Lesley Gilmour; Katrina H Stevenson; Ester M Hammond; Anthony J Chalmers
Journal:  Cancer Res       Date:  2018-07-05       Impact factor: 12.701

Review 9.  Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications.

Authors:  Tamara J Abou-Antoun; James S Hale; Justin D Lathia; Stephen M Dombrowski
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

10.  Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.

Authors:  Jeremy Karlin; Jasmine Allen; Syed F Ahmad; Gareth Hughes; Victoria Sheridan; Rajesh Odedra; Paul Farrington; Elaine B Cadogan; Lucy C Riches; Antonio Garcia-Trinidad; Andrew G Thomason; Bhavika Patel; Jennifer Vincent; Alan Lau; Kurt G Pike; Thomas A Hunt; Amrita Sule; Nicholas C K Valerie; Laura Biddlestone-Thorpe; Jenna Kahn; Jason M Beckta; Nitai Mukhopadhyay; Bernard Barlaam; Sebastien L Degorce; Jason Kettle; Nicola Colclough; Joanne Wilson; Aaron Smith; Ian P Barrett; Li Zheng; Tianwei Zhang; Yingchun Wang; Kan Chen; Martin Pass; Stephen T Durant; Kristoffer Valerie
Journal:  Mol Cancer Ther       Date:  2018-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.